Cue Biopharma, Inc. (CUE) Stock

Cue Biopharma, Inc. is an innovative clinical-stage biopharmaceutical firm dedicated to advancing biologic drugs tailored for precise modulation of the human immune system. With a focus on treating a spectrum of conditions including cancers, chronic infectious diseases, and autoimmune disorders, Cue Biopharma is at the forefront of developing transformative therapies.

At the forefront of its pipeline is CUE-101, a fusion protein biologic currently in Phase 1b clinical trials. This drug candidate is specifically designed to activate antigen-specific T cells targeted against human papilloma virus-driven cancers. In addition to CUE-101, the company is developing CUE-102, another fusion protein biologic aimed at enhancing T cell response against cancers.

Cue Biopharma's innovation extends to CUE-103, a member of its CUE-100 series Immuno-STATs, which targets the KRAS G12V mutation seen in colorectal carcinoma, lung cancer, and pancreatic cancer. The company's diverse portfolio also includes CUE-200, designed to address T cell exhaustion associated with chronic infections by targeting cell surface receptors like CD80 and/or 4-1BBL. Moreover, CUE-300 and CUE-400 frameworks are under development to target a range of autoimmune diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Cue Biopharma, Inc. collaborates extensively with industry leaders and academic institutions. Partnerships with Merck Sharp & Dohme Corp., LG Chem Life Sciences, and Albert Einstein College of Medicine underscore its commitment to advancing biologics research and development. Formerly known as Imagen Biopharma, Inc., Cue Biopharma, Inc. continues to pioneer innovative therapies aimed at transforming patient care through cutting-edge immunotherapy solutions.